+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peanut Allergy - Pipeline Insight, 2020

  • ID: 4037218
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 75 pages
  • DelveInsight

FEATURED COMPANIES

  • Aimmune Therapeutics
  • AnaptysBio
  • Astellas Pharma
  • DBV Technologies
  • HAL Allergy
  • Mast Cell Pharmaceuticals
The “Peanut Allergy - Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the rapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Peanut Allergy Understanding

Peanut Allergy: Overview

A peanut allergy is a reaction that occurs when the body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system - the body's natural defense system that fights infections and diseases - overreacts and can cause a serious, even life-threatening response.

Symptoms

The most severe allergic reaction to peanuts is anaphylaxis - a life-threatening whole-body response to an allergen. Symptoms may include impaired breathing, swelling in the throat, a sudden drop in blood pressure, pale skin or blue lips, fainting and dizziness. Anaphylaxis should be treated immediately with epinephrine (adrenaline), typically administered in an auto-injector.

Symptoms of a peanut allergy may include:
  • Vomiting
  • Stomach cramps
  • Indigestion
  • Diarrhea
  • Wheezing
  • Shortness of breath, difficulty breathing
  • Repetitive cough
  • Tightness in throat, hoarse voice
  • Weak pulse
  • Pale or blue coloring of the skin
  • Hives
  • Swelling, can affect the tongue and/or lips
  • Dizziness
  • Confusion
Diagnosis

To diagnose a peanut allergy, the doctor will start with a medical history and a physical exam. he will ask about any family food allergies, especially siblings with peanut allergies. He or she will ask detailed questions about symptoms, how soon symptoms began after the patient ate the food, and if any over-the-counter allergy medicines like an antihistamine were helpful. The doctor will ask if other people also got sick, how the food was prepared, and what other foods were eaten.

It's important to find out whether the patient have a food allergy or food intolerance. He or she may ask to keep a record of all the foods patient’s eat and any reactions to the foods. The doctor will also consider if a reaction could have been caused by things like allergies, medicines, insect stings, food poisoning, irritants in foods, or exposure to skin irritants.

Treatment

For a mild reaction, to reduce the symptoms, the patient may only need to take an antihistamine, such as a nondrowsy one like loratadine (Claritin) or one that might make the patient sleepy like diphenhydramine (Benadryl). Mild symptoms include sneezing or an itchy or runny nose; an itchy mouth; a few hives or mild itching; and mild nausea or stomach discomfort. If the patient have had a severe reaction previously, the doctor has probably prescribed a medicine called epinephrine.

Peanut Allergy Emerging Drugs Chapters

This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peanut Allergy Emerging Drugs

Viaskin Peanut: DBV Technologies

DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. Viaskin® Peanut is currently being investigated in clinical trials for treatment of peanut allergy.

Dupilumab: Regeneron Pharmaceuticals/Sanofi

Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development.

Etokimab: AnaptysBio

Etokimab is a first-in-Class anti-IL-33 antibody that is being developed AnaptysBio for the treatment of Peanut allergy. Efficacy and safety has previously been reported in adult moderate-to-severe atopic dermatitis and severe adult peanut allergy patients. It is currently in phase II stage of development.

ASP0892: Astellas pharma

ASP0892 is a next generation vaccine that is being developed by Astellas pharma for the treatment of Peanut allergy. It is currently in phase I stage of development.

CNP 201: Cour Pharmaceutical Development

CNP 201 is being developed by Cour Pharmaceutical Development for the treatment of Peanut allergy. It is currently in preclinical stage of development.

Peanut Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Peanut Allergy drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Peanut Allergy

There are approx. 20+ key companies which are developing the rapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. phase III include DBV Technologies and others.

This report covers around 20+ products under different phases of clinical development like
  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Peanut Allergy pipeline report provides the rapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Gene therapies
  • Small molecule
  • Vaccines
  • Polymers
  • Peptides
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peanut Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. the rapies under development are focused on novel approaches to treat/improve Peanut Allergy.
  • In October 2019, DBV Technologies announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for its investigational Viaskin Peanut immunotherapy for the treatment of peanut-allergic children ages 4 to 11 years.
  • In April 2015 DBV Technologies stated that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Viaskin Peanut for children.
  • In 2012, Viaskin Peanut received Fast Track Designation from the FDA in 2012.
Peanut Allergy Report Insights
  • Peanut Allergy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Peanut Allergy Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Peanut Allergy drugs?
  • How many Peanut Allergy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peanut Allergy and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Regeneron Pharmaceuticals
  • Novartis
  • Aimmune Therapeutics
  • AnaptysBio
  • DBV Technologies
  • HAL Allergy
  • Astellas Pharma
  • Mast Cell Pharmaceuticals
  • Vedanta Biosciences, Inc.
  • Cour Pharmaceutical Development
Key Products
  • Dupilumab
  • QGE031
  • AR101
  • Viaskin Peanut
  • ANB020
  • HAL-MPE1
  • ASP0892
  • Ketotifen
  • CNP 201
  • VE416

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aimmune Therapeutics
  • AnaptysBio
  • Astellas Pharma
  • DBV Technologies
  • HAL Allergy
  • Mast Cell Pharmaceuticals
Introduction

Executive Summary

Peanut Allergy: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Peanut Allergy – Analytical Perspective

In-depth Commercial Assessment
  • Peanut Allergy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Peanut Allergy Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Viaskin Peanut: DBV Technologies
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • Product Description
  • Research and Development
  • Product Development Activities
Etokimab: AnaptysBio
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
ASP0892: Astellas pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
CNP 201: Cour Pharmaceutical Development
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Peanut Allergy Key Companies

Peanut Allergy Key Products

Peanut Allergy- Unmet Needs

Peanut Allergy- Market Drivers and Barriers

Peanut Allergy- Future Perspectives and Conclusion

Peanut Allergy Analyst Views

Peanut Allergy Key Companies

Appendix

List of Tables
Table 1 Total Products for Peanut Allergy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Peanut Allergy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Regeneron Pharmaceuticals
  • Novartis
  • Aimmune Therapeutics
  • AnaptysBio
  • DBV Technologies
  • HAL Allergy
  • Astellas Pharma
  • Mast Cell Pharmaceuticals
  • Vedanta Biosciences, Inc.
  • Cour Pharmaceutical Development
Note: Product cover images may vary from those shown
Adroll
adroll